Pharmarise Holdings net sales up, profitability impacted by revisions

Pharmarise Holdings Corporation (TSE:2796) reported a 16.6% year-on-year increase in net sales, reaching JPY 63,508 million for the fiscal year ended May 31, 2025. However, operating profit plummeted 67.9% to JPY 293 million, and the company recorded a loss attributable to owners of parent of JPY 367 million. The decline in profitability was attributed to dispensing fee and drug price revisions, increased costs from a volatile purchasing environment, higher labor costs, and expenses related to M&A activities, including the acquisition of GOOD AID Group and the business transfer from the Kanichi Shoten Group.